Orthofix Medical: Navigating Policy Shifts for Future Growth

Rewey Asset Management's Q2 2026 Insights on Market Performance

Rewey Asset Management's latest investor letter for Q2 2026 revealed strong market performance, with its RAM Smid Composite achieving a 20.06% gain, surpassing the Russell 2500 Value Total Return Index's 18.50%. Year-to-date, the composite's performance reached 31.15%, significantly outperforming the benchmark's 24.16%. This robust showing, coupled with the Russell 2500 Value's outperformance against the S&P 500 and the Magnificent 7, suggests a continuing market shift towards undervalued small and mid-cap equities. Despite a moderation in economic growth following first-quarter GDP revisions, capital markets remained dynamic, highlighted by $104 billion raised through 48 IPOs.

Orthofix Medical's Position in the Medical Technology Landscape

Orthofix Medical Inc. (NASDAQ: OFIX), a prominent player in medical technology, was a key focus in Rewey Asset Management's second-quarter 2026 investor letter. As of July 22, 2026, OFIX shares closed at $11.02, demonstrating a 27.03% one-month return and a 4.14% gain over the preceding 52 weeks. The company commands a market capitalization of $441.80 million, with its shares trading within a 52-week range of $8.85 to $16.99. These metrics highlight the company's significant presence and recent upward momentum in the stock market.

Impact of CMS Reimbursement Reversal on Orthofix Medical

Rewey Asset Management specifically addressed Orthofix Medical Inc. in its Q2 2026 letter, noting that OFIX had been its weakest performer in Q1 2026. This downturn followed a May 21st announcement that the Centers for Medicare & Medicaid Services (CMS) had reduced reimbursement rates for non-invasive bone growth stimulator devices. Consequently, OFIX revised its 2026 revenue guidance downwards by $5 million and withdrew its prior three-year targets. However, in a significant turnaround on July 1st, CMS completely reversed this code change, transforming a substantial headwind into a positive catalyst for OFIX. Rewey Asset Management believes that while the initial news was disappointing, the policy reversal underscores that the challenge was not intrinsic to the company's operations. The firm maintains its forecast for OFIX's revenue and earnings growth over the coming years, viewing the prior share decline as an overreaction to a temporary setback.

Investment Considerations and Comparative Analysis for OFIX

Despite its recent positive developments, Orthofix Medical Inc. (NASDAQ: OFIX) is not among the top 40 most popular stocks favored by hedge funds, with 21 hedge fund portfolios holding OFIX at the close of the first quarter, down from 24 in the previous quarter. While acknowledging OFIX's investment potential, other investment opportunities, particularly in the artificial intelligence sector, are perceived to offer greater upside with reduced downside risk. For investors seeking highly undervalued AI stocks that could benefit from evolving trade policies and domestic manufacturing trends, a separate analysis on leading short-term AI stocks is recommended. This broader perspective helps contextualize OFIX's appeal within a diverse investment landscape, encouraging a balanced approach to portfolio construction.